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The relationship between the magnitude of systemic inﬂammatory response and the nutritional/functional parameters in
patients with inoperable non-small cell lung cancer were studied. The extent of weight loss, albumin, C-reactive protein,
performance status and quality of life was measured in 106 patients with inoperable non-small cell lung cancer (stages III and
IV). Survival analysis was performed using the Cox proportional hazard model. The majority of patients were male and almost
80% had elevated circulating C-reactive protein concentrations (410 mg l
71). On multivariate analysis, age (P=0.012),
tumour type (0.002), weight loss (P=0.056), C-reactive protein (P=0.047), Karnofsky performance status (P=0.002) and fatigue
(P=0.046) were independent predictors of survival. The patients were grouped according to the magnitude of the C-reactive
protein concentrations (410, 11–100 and 4100 mg l
71). An increase in the magnitude of the systemic inﬂammatory
response was associated with increased weight loss (P=0.004), reduced albumin concentrations (P=0.001), reduced
performance status (P=0.060), increased fatigue (P=0.011) and reduced survival (HR 1.936 95%CI 1.414–2.650, P50.001).
These results indicate that the majority of patients with inoperable non-small cell lung cancer have evidence of a systemic
inﬂammatory response. Furthermore, an increase in the magnitude of the systemic inﬂammatory response resulted in greater
weight loss, poorer performance status, more fatigue and poorer survival.
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Lung cancer is the commonest cause of cancer death in North Amer-
ica and western Europe. Each year in the United Kingdom there are
almost 39000 new cases registered; only 5% are alive at 5 years (2001
CRC Cancerstats, www.cancerresearchuk.org). Most patients present
with advanced inoperable disease, few are amenable to surgery and
the results of radiotherapy and chemotherapy are poor.
In patients with advanced cancer, progressive weight loss is
common and leads to a reduction in performance status and qual-
ity of life (O’Gorman et al, 1999, 2000). However, in the absence of
a clear understanding of the underlying mechanisms, management
of these problems has been largely ineffective (Fearon et al, 2001).
Therefore, it is of interest that the presence of a systemic inﬂam-
matory response (as evidenced by increased circulating
concentrations of C-reactive protein) has recently been shown to
be associated with loss of weight (Scott et al, 1996; McMillan et
al, 1998) and a reduction of performance status (O’Gorman et
al, 1998; Barber et al, 1999) in patients with advanced lung and
gastrointestinal cancer. There is also evidence that the systemic
inﬂammatory response is predictive of survival, independent of
stage, in advanced gastrointestinal cancer (Falconer et al, 1995;
O’Gorman et al, 2000).
The results of the above studies suggest that the systemic inﬂam-
matory response may contribute directly to the progressive decline
in nutritional and functional status in the patient with advanced
cancer. If this were so, one might expect that not only the presence,
but also the magnitude, of the systemic inﬂammatory response
would be important. However, the nature of the relationship
between the magnitude of systemic inﬂammatory response and
the loss of weight, performance status and quality of life in patients
with advanced lung cancer is not clear.
The aim of the present study was to examine the relationship
between the magnitude of the systemic inﬂammatory response
and weight loss, performance status and survival in patients with
inoperable NSCLC.
MATERIALS AND METHODS
Study design
Patients presenting between January 1995 and November 1998 with
inoperable NSCLC (stages III and IV) were included in the study.
All patients had cytologically or histologically conﬁrmed disease
and had no clinical or radiological evidence of infection. The
patients were staged according to the American Thoracic Society
TNM classiﬁcation on the basis of clinical ﬁndings, chest X-ray,
and where appropriate, bronchoscopy, liver ultrasound, isotope
bone scan and computerised tomography of the thorax (Mountain,
1991).
The extent of weight loss, Karnofsky performance status and
quality of life were measured at the time of diagnosis. A blood
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min and C-reactive protein concentrations.
All patients were followed to death.
The study was approved by the Research Ethics Committee of
Stobhill NHS Trust, Glasgow, UK. All subjects were informed of
the purpose and procedure of the study and all gave written
consent.
Methods
Weight loss Weight loss was deﬁned as loss of more than 5%
pre-illness weight in the previous 6 months.
Karnofsky performance status Performance status was assessed
using this numerical scale, and a score was given depending on
the level of independence (Mor et al, 1984).
EORTC QLQ-C30 Different aspects of quality of life were
assessed using this cancer speciﬁc 30-item questionnaire, which
has six functional scales (physical, role, emotional, cognitive, social,
global health status) and several questions relating to a range of
physical symptoms (Aaronson et al, 1993). Patients marked to what
extent each statement applied to them.
Blood parameters Routine laboratory measurement of haemo-
globin, albumin and C-reactive protein concentration was carried
out. The coefﬁcient of variation for these methods, over the range
of measurement, was less than 5% as established by routine quality
control procedures.
Statistics
Data are presented as median and range. Where appropriate,
comparison of patient groups was carried out using the Kruskal-
Wallis test for analysis of variance.
Survival analysis was performed using the Cox proportional
hazard model with patients’ age, sex, stage, histological type, weight
loss, haemoglobin, albumin, C-reactive protein, Karnofsky perfor-
mance status and EORTC QLQ-C30 subscales as prognostic
variables.
Multivariate survival analysis was performed using a stepwise
backward procedure to derive a ﬁnal model of the variables that
had a signiﬁcant independent relationship with survival. To remove
a variable from the model, the corresponding P-value had to be
greater than 0.10. Survival curves were analysed by the Kaplan-
Meier method. In terms of the relationship between the systemic
inﬂammatory response and survival it was assumed that any pallia-
tive treatment following measurements at diagnosis had no
signiﬁcant impact on the duration of survival.
Analysis was performed using SPSS software (SPSS Inc., Chica-
go, Illinois, USA).
RESULTS
The characteristics of patients with inoperable NSCLC (n=106) are
shown in Table 1. The majority of patients were male, over the age
of 60 years and had stage III disease. Approximately 40% had more
than 5% weight loss and almost 80% had elevated circulating C-
reactive protein concentrations (410 mg l
71). The median
Karnofsky performance status was 70. All scores of the EORTC-
QLQ C30 functional scales were poor (50 or less); also, the fatigue
scale scores were poor (50 or more). Median survival from the
time of diagnosis was 5.2 (range 0.3–38.5) months.
On univariate analysis, stage (P=0.020), tumour type
(P50.001), albumin (P=0.002) and C-reactive protein (P=0.004)
concentrations, Karnofsky performance status (P50.001), physical
functioning (P=0.013), fatigue (P50.001), pain (P=0.045) and
appetite loss (P=0.004) were signiﬁcant predictors of survival. On
multivariate analysis, only age (HR 1.040 95% CI 1.009–1.072,
P=0.012), tumour type (HR 1.655, 95% CI 1.200–2.282,
P=0.002), weight loss (HR 0.605 95% CI 0.362–1.012, P=0.056),
C-reactive protein (HR 1.783 95% CI 1.009–3.151, P=0.047),
Karnofsky performance status (HR 0.964 95% CI 0.942–0.987,
P=0.002) and fatigue (HR 1.011 95% CI 1.000–1.022, P=0.046)
remained signiﬁcant independent predictors of survival.
Patients were then grouped according to the magnitude of the
C-reactive protein concentrations namely 410, 11–100 and
4100 mg l
71 as previously described (McMillan et al, 2001; Table
2). The distribution of sex, age and stage was similar between these
groups. An increase in the magnitude of the systemic inﬂammatory
response was associated with an increase in the relative proportion
of non-adenocarcinoma (P=0.014), increased weight loss
(P=0.004), reduced haemoglobin (P50.001) and albumin concen-
trations (P50.001) and reduced performance status (P=0.060).
With the exception of fatigue (P=0.011), there was no signiﬁcant
relationship between the magnitude of the systemic inﬂammatory
response and the EORTC QLQ C-30 subscale scores.
Median survival ranged from 11 months in those with a C-reac-
tive protein concentration of 10 mg l
71 or less, to 3 months for
those with a C-reactive protein concentration greater than
100 mg l
71 (HR 1.936 95% CI 1.414–2.650, P50.001).
DISCUSSION
In the present study of patients with inoperable NSCLC, the
presence of a systemic inﬂammatory response was associated with
increased weight loss, a reduction in performance status, increased
fatigue and reduced survival. This is consistent with previous
studies, in patients with lung cancer, showing that the presence
of a systemic inﬂammatory response is associated with an increase
in resting energy expenditure (Staal-van den Brekel et al, 1995;
Scott et al, 2001), loss of lean tissue (McMillan et al, 1998; Simons
et al, 1999), decreased performance status and survival (Martin et
al, 1999).
If the relationship between the presence of a systemic inﬂamma-
tory response was causal, an increase in the magnitude of the
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Table 1 Clinical and quality of life characteristics of patients with inoper-
able NSCLC
NSCLC patients (n=106)
Sex (male/female) 62/44
Age (years) 69 (43–87)
Stage (III/IV) 78/28
Type (S/A/O) 37/20/49
Weight-loss (55%/55%) 61/45
Haemoglobin (g l
71) 12.2 (8.9–16.9)
Albumin (g l
71) 39 (24–49)
C-reactive protein (mg l
71)4 0 ( 55–240)
Karnofsky performance status
80–90/60–70/450 42%/44%/9%
EORTC QLQ-C30
Physical functioning 40
Role functioning 50
Emotional functioning 41.7
Cognitive functioning 33.3
Social functioning 33.3
Quality of life 50
Fatigue 55.5
Pain 16.7
Appetite loss 33.3
Survival from diagnosis (months) 5.2 (0.3–38.5)
Median (range); S, squamous; A, adenocarcinoma; O, other.
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performance status and survival. It is therefore of interest that in
the present study, exponential increases in circulating concentrations
of C-reactive protein were associated with increased weight loss,
reduced performance status, increased fatigue and decreased survival.
These results would suggest that a common mechanism underlies the
progressive nutritional and functional decline of patients with inop-
erable NSCLC, which ultimately impacts on survival.
The mechanism by which a systemic inﬂammatory response
might inﬂuence cancer survival is not clear. However, it is known
that as part of the systemic inﬂammatory response, there is a
release of pro-inﬂammatory cytokines and growth factors (Fearon
et al, 1991; Moldawer and Copeland, 1997) some of which produce
metabolic disturbances (McMillan et al, 1994; Barber et al, 2000)
and loss of lean tissue (McMillan et al, 1998). The presence of
these factors may also promote tumour growth (Moldawer and
Copeland, 1997; Abramovitch et al, 1999) which, in turn, may
further stimulate the systemic inﬂammatory response.
The speciﬁc factors which determine the magnitude of the
systemic inﬂammatory response evoked in patients with inoperable
NSCLC are not clear. The systemic inﬂammatory response may be
secondary to tumour necrosis or local tissue damage caused by the
tumour-host cell interaction. It is of interest that, although in the
present study the magnitude of the systemic inﬂammatory response
was not associated with disease stage it was associated with a
decrease in the proportion of adenocarcinomas. It may be that
the non-adenocarcinoma phenotype preferentially stimulates a
systemic inﬂammatory response.
In summary, the results of the present study indicate that the
majority of patients with inoperable NSCLC have evidence of a
systemic inﬂammatory response at the time of diagnosis. Further-
more, the greater the magnitude of the systemic inﬂammatory
response, the greater the weight loss, the poorer the performance
status, the greater the fatigue and the poorer the survival.
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